

Press Release

Kraig Biocraft Laboratories, Inc. Develops Synthetic Enzyme

- DNA Sequence for New Enzyme is Mapped. In Vitro Testing of the Enzyme's Ability to Cleave the Targeted DNA to Begin this Summer -

LANSING, MI - May 20, 2008 -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced today that a leading university laboratory, working pursuant to Kraig's collaborative and sponsored research program, has mapped out the DNA sequence for a new enzyme. The new enzyme is being developed as an important part of the laboratories' work with Kraig in developing new high strength polymers based on spider silk. The enzyme will be used to cleave targeted DNA sequences so as to facilitate genetic manipulation for polymer synthesis.

"We have designed the enzyme specifically to accelerate our work on spider silk polymers," said Dr. Malcolm Fraser, who is the head of the University of Notre Dame research laboratory conducting this work. "The enzyme should be ready for in vitro testing this summer. Because the enzyme is site specific, it will only cleave our targeted DNA at the precise target point. It is the biochemical equivalent of a rifle shot."

The development of the enzyme fulfills an important part of the Company's collaborative research plan with the University. "This success is rightly credited to Dr. Fraser and his team," said Kraig's CEO Kim Thompson. "With the mapping of this DNA sequence our development program has taken another big leap forward. The benefit to Kraig's work on spider silk polymers is immeasurable. We believe that this exciting finding will play an important role in the development of high strength polymers and platform technologies."

Kraig Biocraft Laboratories is a technology company focused on the development of commercially significant high-performance polymers, technical fibers and diverse platform technologies. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including spider silk for use in the multi-billion dollar technical fibers market.

For more information on Kraig Biocraft Laboratories please visit the Company's website: <http://www.KraigLabs.com>

An audio interview discussing Kraig's vision and corporate developments is also available on the website.

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believe," "plans," "expects,"

"anticipates," "efforts," "foresees," "future," "forecasts," "estimates," "intends," "develops," "researching," "research," "goal," "potential," "possibility," "pursue," "could," "should" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions, marketing strategies, or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products and execute on its marketing plans may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
(517) 336-0807
info@KraigLabs.com